LivaNova PLC
LIVNNasdaq
$80.70
↓ -1.3%Jul 17 close · end-of-day
Price
1Y↑ +87.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.5B
Enterprise Value
$4.3B
P/E
41.2
P/S
3.1
P/B
3.7
EV/EBITDA
19.1
PEG
—
FCF Yield
3.6%
Dividend Yield
—
Revenue (TTM)
$1.4B
Net Income (TTM)
$107.1M
Free Cash Flow (TTM)
$161.0M
Gross Margin
67.5%
Operating Margin
13.4%
Net Margin
7.5%
ROE
8.8%
ROIC
17.7%
Debt / Equity
0.2
Net Cash
$254.4M
Return 1Y
+89.7%
Company profile
LivaNova PLC designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The company has a research collaboration with Verily to capture clinical biomarkers of depression.
- CEO
- Damien McDonald
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 2,900
- Website
- livanova.com
Management & directors
- Tezel AhmetChief Innovation Officer
- Bolton StephaniePresident, Global Epilepsy
- Kozmina NataliaChief Human Resources Officer
- Makatsaria VladimirChief Executive Officer
- Poletti FrancoPresident, Cardiopulmonary
- Shvartsburg AlexChief Financial Officer
- Hutchinson Michael DavidSVP, CLO and Company Secretary
Roles derived from SEC Form 4 filings.
Earnings
LIVN Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$362.3M↑ +14.3%
Diluted EPS$0.40↓ -106.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $934.2M | $1.0B | $1.0B | $1.2B | $1.3B | $1.4B |
| Gross profit | $594.8M | $706.0M | $707.2M | $755.8M | $853.5M | $939.9M |
| Operating income | -$273.9M | -$784,000.00 | -$76.8M | -$68.5M | $129.1M | $199.4M |
| Net income | -$348.8M | -$135.8M | -$86.2M | $17.6M | $63.2M | -$242.5M |
| Diluted EPS | -$7.18 | -$2.68 | -$1.61 | $0.32 | $1.16 | -$4.45 |
| Operating cash flow | -$79.4M | $102.5M | $69.9M | $74.9M | $183.0M | $254.3M |
| Free cash flow | -$114.4M | $77.1M | $43.4M | $39.9M | $135.9M | $173.3M |
| Gross margin | 63.7% | 68.2% | 69.2% | 65.5% | 68.1% | 67.7% |
| Operating margin | -29.3% | -0.1% | -7.5% | -5.9% | 10.3% | 14.4% |
| Net margin | -37.3% | -13.1% | -8.4% | 1.5% | 5.0% | -17.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $318.6M | $318.1M | $321.8M | $316.9M | $352.5M | $357.8M | $360.9M | $362.3M |
| Gross profit | $214.9M | $221.0M | $214.4M | $216.3M | $239.0M | $244.9M | $239.8M | $243.7M |
| Operating income | $40.2M | $35.6M | $37.0M | $48.6M | $54.2M | $54.0M | $42.6M | $41.5M |
| Net income | $16.3M | $33.0M | $55.9M | -$327.3M | $27.2M | $26.8M | $30.9M | $22.3M |
| Diluted EPS | $0.30 | $0.60 | $1.04 | -$6.01 | $0.50 | $0.49 | $0.57 | $0.40 |
| Operating cash flow | $43.4M | $51.0M | $78.7M | $24.0M | $62.9M | $85.1M | $82.4M | $15.2M |
| Free cash flow | $31.2M | $32.8M | $68.3M | $13.2M | $47.8M | $62.2M | $50.2M | $926,000.00 |
| Gross margin | 67.4% | 69.5% | 66.6% | 68.3% | 67.8% | 68.4% | 66.4% | 67.3% |
| Operating margin | 12.6% | 11.2% | 11.5% | 15.3% | 15.4% | 15.1% | 11.8% | 11.4% |
| Net margin | 5.1% | 10.4% | 17.4% | -103.3% | 7.7% | 7.5% | 8.6% | 6.2% |
Company news
Jun 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-15 | Bianchi Francesco | Sale | 1,200 | $80.19 | $96,228.00 | filing |
| 2026-06-15 | Tezel Ahmet· Chief Innovation Officer | Tax withholding | 1,032 | $79.70 | $82,250.40 | filing |
| 2026-06-15 | KOZY WILLIAM A | Tax withholding | 682 | $79.70 | $54,355.40 | filing |
| 2026-06-15 | SCHERMERHORN TODD C | Tax withholding | 486 | $79.70 | $38,734.20 | filing |
| 2026-06-15 | Story Brooke | Tax withholding | 486 | $79.70 | $38,734.20 | filing |
| 2026-06-15 | PODLOGAR SUSAN M | Tax withholding | 486 | $79.70 | $38,734.20 | filing |
| 2026-06-15 | Barry James Christopher | Tax withholding | 486 | $79.70 | $38,734.20 | filing |
| 2026-06-15 | Bianchi Francesco | Tax withholding | 486 | $79.70 | $38,734.20 | filing |
| 2026-06-15 | Enxing Seng Stacy | Tax withholding | 486 | $79.70 | $38,734.20 | filing |
| 2026-06-15 | WILVER PETER M | Tax withholding | 486 | $79.70 | $38,734.20 | filing |
| 2026-06-15 | Zurbay Donald | Tax withholding | 308 | $79.70 | $24,547.60 | filing |
| 2026-06-15 | Barry James Christopher | Option exercise | 4,042 | $0.00 | $0.00 | filing |
| 2026-06-15 | WILVER PETER M | Option exercise | 4,042 | $0.00 | $0.00 | filing |
| 2026-06-15 | SCHERMERHORN TODD C | Option exercise | 4,042 | $0.00 | $0.00 | filing |
| 2026-06-15 | Bianchi Francesco | Option exercise | 4,042 | $0.00 | $0.00 | filing |
| 2026-06-15 | PODLOGAR SUSAN M | Option exercise | 4,042 | $0.00 | $0.00 | filing |
| 2026-06-15 | Tezel Ahmet· Chief Innovation Officer | Option exercise | 2,965 | $0.00 | $0.00 | filing |
| 2026-06-15 | KOZY WILLIAM A | Option exercise | 5,681 | $0.00 | $0.00 | filing |
| 2026-06-15 | Enxing Seng Stacy | Option exercise | 4,042 | $0.00 | $0.00 | filing |
| 2026-06-15 | Story Brooke | Option exercise | 4,042 | $0.00 | $0.00 | filing |
| 2026-06-15 | Zurbay Donald | Option exercise | 2,560 | $0.00 | $0.00 | filing |
| 2026-05-26 | Bianchi Francesco | Sale | 1,800 | $75.75 | $136,350.00 | filing |
| 2026-03-30 | Shvartsburg Alex· Chief Financial Officer | Tax withholding | 12,868 | $61.27 | $788,422.36 | filing |
| 2026-03-30 | Makatsaria Vladimir· Chief Executive Officer | Tax withholding | 11,159 | $61.27 | $683,711.93 | filing |
| 2026-03-30 | Bolton Stephanie· President, Global Epilepsy | Tax withholding | 8,377 | $61.27 | $513,258.79 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.